PDUFA V: What you need to know about the upcoming Prescription Drug User Fee Act
Rho
Oncology News | |
 |
Oncology is one of the most active areas of research in the pharmaceutical industry with, according to recent PhRMA figures, more than 900 new cancer drugs being developed by US companies alone. The contract research sector has been quick to recognise this demand with barely a week going by without news of a cancer trial partnership or new oncology-focused service launch. With this trend in mind, on July 12th Outsourcing-pharma.com is holding Oncology Trials Outsourcing an industry-first virtual conference focused on the role outsourcing can play in the successful development of cancer drugs. Experts from Cutting Edge Information, INC Research, Quintiles and Eli Lilly will lead our webinar programme, sharing their thoughts on the important issues and instantly fielding questions from you, our online audience. Sign up to "attend" our innovative, online only event for free here . |
Ockham buys Nexus in bid to boost oncology trial offering
Ockham has expanded its oncology trial services offering through its acquisition of Nexus Oncology.
J&J hunting for new CMO for Doxil
Supplies of Johnson & Johnson’s Doxil cancer drug will be cut down in coming months as the company transitions to a new manufacturer.
US-based START open Phase I cancer research center in Shanghai
Anti-cancer clinical trial specialist, South Texas Accelerated Therapeutics (START), has collaborated with China's largest cancer hospital to open a new Phase I cancer research center.
Sareum sees hike in share prices thanks to inhibitor
Shares in drug discovery company Sareum have soared by 36 per cent after the firm announced the selection of a preclinical development candidate for its Checkpoint kinase 1 (Chk1) inhibitor programme.
vivoPharm branch out in US with MPI partnership and new Hershey office
vivoPharm has extended its oncology offering after striking up an alliance with MPI Research.
Synteract talks rescue studies at DIA 2011
Synteract says the use of non-validated data systems in clinical trials is a key driver for the ‘rescue study’ segment of the contract research sector.
Changing Times: The Need For a Logical Sourcing Strategy
Sponsors need to abandon the ‘single trial, random, tactical sourcing approach’ in favour of a model flexible enough for a variety of study designs and research needs according to Eli Lilly experts Lee Scheible and Jeffrey S Kasher in this exclusive guest article.
SCM Pharma teams with SEP in cancer product manufacturing deal
UK-based contract manufacturing organisation (CMO) SCM Pharma has struck a deal with urology experts Speciality European Pharma (SEP) to help bring SEP's oncology product, Plenaxis, to the European market.
Veeda Oncology launches virtual trial management service for cancer clinics
US-based Veeda Oncology has launched a new service designed to help community cancer practices manage clinical trials.
Quintiles in genomics partnership with PGT
Quintiles has signed a deal with Population Genetics Technologies (PGT) that, it says, will bring large-scale genomics analysis into the drug development mainstream.
Quintiles backs I-SPY-2 breast cancer trial
Quintiles has leant its support to I-SPY 2, an innovative clinical trial designed to accelerate the development of treatments for breast cancer.
VisualSonics unveils ‘revolutionary’ Vevo LAZR imaging system
VisualSonics, a high-resolution micro imaging systems manufacturer, has launched a new imaging system it claims will revolutionise cancer research.
Aptiv Solutions and Cancer Genetics team on cancer trial services
Aptiv Solutions and Cancer genetics have partnered to provide biopharmaceutical developers with support for cancer trials.
UK CROs extend preclinical cancer partnership
Preclinical Oncology Services Limited (Precos) will to work with discovery services firm Argenta Discovery on cancer drug development projects under a revised collaboration agreement announced late yesterday.
Kancera buys CRO iNovacia
Sweden-based cancer drug specialist Kancera has bought Stockholm-headquartered discovery and development services provider iNovacia.
Role for CROs as study deems cancer trials biggest risk for Pharmas
Late-stage cancer trials are the biggest challenge for pharmaceutical and biotech firms according to data presented at the Biotechnology Industry Organisation's (BIO) CEO and investor conference in Washington DC, US this week.
Pool of US cancer investigators needed to boost recruitment
A pool of research-aware US oncology clinical investigators must be developed to ensure patient recruitment rates meet demand.
Ohio site joins US Oncology Research Phase I network
US Oncology Research has added a site in Dayton, Ohio, US to its network of Phase I cancer research centres.
Christie cancer centre opens early phase trials unit to help fight cancer
The Christie cancer centre in Manchester, UK, has opened a £35m (€41m) early phase clinical trial unit to help develop new treatments for a range of cancers.
PBS-Bio inks deals to speed up cancer drug development
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon and Cylene to better patient selection in cancer drug development deal
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
CRL expands cancer model offering with p53 and BCrp rats
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Chinese cancer drug brings HUYA and Quintiles together
HUYA Bioscience International will co-develop a new Chinese cancer drug, HBI-8000, with Quintiles for the “benefit of cancer patients globally.”
GSK taps NCCN for cancer drug trials
GSK has awarded the National Comprehensive Cancer Network (NCCN) grants worth $4m to support trials involving ofatumumab and pazopanib.
BNC lands cancer drug formulation contract
Bio Nano Consulting (BNC) says University of London School of Pharmacy deal helped land first Ph I trial formulation services contract.
Biomarkers “indispensible” in cancer drug development, says Quintiles
CRO Quintiles says biomarkers give insight into cancer drug candidates’ efficacy earlier in the development process, reducing trial costs and duration.
FDA issues cancer vaccine trial guidance
Clinical trials of cancer vaccines should enrol patients with no evidence of residual disease, according to FDA guidance, but this will increase development times compared to cytotoxic agents.
Spotlight
  Marken mulls direct-to-study participant distributionMarken is looking at setting up a home delivery service as a further expansion of its clinical... |